Short-term isocaloric fructose restriction lowers apoC-III levels and yields less atherogenic lipoprotein profiles in children with obesity and metabolic syndrome

Atherosclerosis

Volumn 253, Issue , 2016, Pages 171-177

  Gugliucci, Alejandro ^a   Lustig, Robert H ^b   Caccavello, Russell ^a   Erkin Cakmak, Ayca ^b   Noworolski, Susan M ^b   Tai, Viva W ^b   Wen, Michael J ^b   Mulligan, Kathleen ^a,b   Schwarz, Jean Marc ^a  

^a Touro University California   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

apoC III; Apolipoproteins; Fructose; HDL subclasses; LDL subclasses; Metabolic syndrome; Obesity

Indexed keywords

APOLIPOPROTEIN B; APOLIPOPROTEIN C2; APOLIPOPROTEIN C3; APOLIPOPROTEIN E; FRUCTOSE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; HDL-TRIGLYCERIDE; HIGH DENSITY LIPOPROTEIN; LIPOPROTEIN; VERY LOW DENSITY LIPOPROTEIN;

ADOLESCENT; ARTICLE; ATHEROGENESIS; BIOCHEMICAL ANALYSIS; CALORIC RESTRICTION; CHILDHOOD OBESITY; CHOLESTEROL BLOOD LEVEL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; INTERVENTION STUDY; LIPID ANALYSIS; MALE; METABOLIC SYNDROME X; PRIORITY JOURNAL; REDUCTION; AFRICAN AMERICAN; ATHEROSCLEROSIS; BLOOD; CHEMISTRY; CHILD; CLINICAL TRIAL; COMPLICATION; DIET; DIET THERAPY; ENZYME LINKED IMMUNOSORBENT ASSAY; HISPANIC; METABOLISM;

ADOLESCENT; AFRICAN AMERICANS; APOLIPOPROTEIN C-III; ATHEROSCLEROSIS; CHILD; DIET; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FRUCTOSE; GLUCOSE; HISPANIC AMERICANS; HUMANS; LIPOPROTEINS; LIPOPROTEINS, HDL; LIPOPROTEINS, LDL; LIPOPROTEINS, VLDL; MALE; METABOLIC SYNDROME; PEDIATRIC OBESITY; TRIGLYCERIDES;

EID: 84978835133     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2016.06.048     Document Type: Article

References (47)

1. [1] Sorof, J.M., Lai, D., Turner, J., Poffenbarger, T., Portman, R.J., Overweight, ethnicity, and the prevalence of hypertension in school-aged children. Pediatrics 113 (2004), 475–482.
2. [2] Kohen-Avramoglu, R., Theriault, A., Adeli, K., Emergence of the metabolic syndrome in childhood: an epidemiological overview and mechanistic link to dyslipidemia. Clin. Biochem. 36 (2003), 413–420.
3. [3] Bacha, F., Saad, R., Gungor, N., Janosky, J., Arslanian, S.A., Obesity, regional fat distribution, and syndrome x in obese black versus white adolescents: race differential in diabetogenic and atherogenic risk factors. J. Clin. Endocrinol. Metab. 88 (2003), 2534–2540.
4. [4] Schwarz, J.M., Noworolski, S.M., Wen, M.J., Dyachenko, A., Prior, J.L., Weinberg, M.E., et al. Effect of a high-fructose weight-maintaining diet on lipogenesis and liver fat. J. Clin. Endocrinol. Metab. 100 (2015), 2434–2442.
5. [5] Malik, V.S., Hu, F.B., Fructose and cardiometabolic health: what the evidence from sugar-sweetened beverages tells us. J. Am. Coll. Cardiol. 66 (2015), 1615–1624.
6. [6] DiNicolantonio, J.J., O'Keefe, J.H., Lucan, S.C., Added fructose: a principal driver of type 2 diabetes mellitus and its consequences. Mayo Clin. Proc. 90 (2015), 372–381.
7. [7] Stanhope, K.L., Schwarz, J.M., Havel, P.J., Adverse metabolic effects of dietary fructose: results from the recent epidemiological, clinical, and mechanistic studies. Curr. Opin. Lipidol. 24 (2013), 198–206.
8. [8] Tg, Hdl Working Group of the Exome Sequencing Project NHL, Blood, I., Crosby, J., Peloso, G.M., Auer, P.L., et al. Loss-of-function mutations in apoC3, triglycerides, and coronary disease. N. Engl. J. Med. 371 (2014), 22–31.
9. [9] Jorgensen, A.B., Frikke-Schmidt, R., Nordestgaard, B.G., Tybjaerg-Hansen, A., Loss-of-function mutations in apoC3 and risk of ischemic vascular disease. N. Engl. J. Med. 371 (2014), 32–41.
10. [10] Hassan, M., Apoc3: triglycerides do matter. Glob. Cardiol. Sci. Pract. 2014 (2014), 241–244.
11. [11] Geach, T., Genetics: apoc3 mutations lower cvd risk. Nat. Rev. Cardiol., 11, 2014, 496.
12. [12] Krauss, R.M., Lipoprotein subfractions and cardiovascular disease risk. Curr. Opin. Lipidol. 21 (2010), 305–311.
13. [13] Feingold, K.R., Grunfeld, C., Pang, M., Doerrler, W., Krauss, R.M., LDL subclass phenotypes and triglyceride metabolism in non-insulin-dependent diabetes. Arterioscler. Thromb. 12 (1992), 1496–1502.
14. [14] Austin, M.A., Breslow, J.L., Hennekens, C.H., Buring, J.E., Willett, W.C., Krauss, R.M., Low-density lipoprotein subclass patterns and risk of myocardial infarction. JAMA 260 (1988), 1917–1921.
15. [15] Martin, S.S., Khokhar, A.A., May, H.T., Kulkarni, K.R., Blaha, M.J., Joshi, P.H., et al. HDL cholesterol subclasses, myocardial infarction, and mortality in secondary prevention: the lipoprotein investigators collaborative. Eur. Heart J. 36 (2015), 22–30.
16. [16] Kontush, A., Lindahl, M., Lhomme, M., Calabresi, L., Chapman, M.J., Davidson, W.S., Structure of hdl: particle subclasses and molecular components. Handb. Exp. Pharmacol. 224 (2015), 3–51.
17. [17] Stanhope, K.L., Medici, V., Bremer, A.A., Lee, V., Lam, H.D., Nunez, M.V., et al. A dose-response study of consuming high-fructose corn syrup-sweetened beverages on lipid/lipoprotein risk factors for cardiovascular disease in young adults. Am. J. Clin. Nutr. 101 (2015), 1144–1154.
18. [18] Lustig, R.H., Mulligan, K., Noworolski, S.M., Tai, V.W., Wen, M.J., Erkin-Cakmak, A., et al. Isocaloric fructose restriction and metabolic improvement in children with obesity and metabolic syndrome. Obes. (Silver Spring) 24 (2016), 453–460.
19. [19] FaN, Board, Dietary reference intakes: energy, carbohydrate, fiber, fat, fatty acids, cholesterol, protein, and amino acids. Macronutrients, 2005 Institute of Medicine, fnic.nal.usda.gov.
20. [20] Guideline: Sugars Intake for Adults and Children, 2015.
21. [21] Matthews, D.R., Hosker, J.P., Rudenski, A.S., Naylor, B.A., Treacher, D.F., Turner, R.C., Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28 (1985), 412–419.
22. [22] Gugliucci, A., Caccavello, R., Kotani, K., Sakane, N., Kimura, S., Enzymatic assessment of paraoxonase 1 activity on HDL subclasses: a practical zymogram method to assess HDL function. Clin. Chim. Acta 415 (2013), 162–168.
23. [23] Cavigiolio, G., Shao, B., Geier, E.G., Ren, G., Heinecke, J.W., Oda, M.N., The interplay between size, morphology, stability, and functionality of high-density lipoprotein subclasses. Biochemistry 47 (2008), 4770–4779.
24. [24] Hersberger, M., von Eckardstein, A., Modulation of high-density lipoprotein cholesterol metabolism and reverse cholesterol transport. Handb. Exp. Pharmacol., 2005, 537–561.
25. [25] Qamar, A., Khetarpal, S.A., Khera, A.V., Qasim, A., Rader, D.J., Reilly, M.P., Plasma apolipoprotein C-III levels, triglycerides, and coronary artery calcification in type 2 diabetics. Arterioscler. Thromb. Vasc. Biol. 35 (2015), 1880–1888.
26. [26] Gibson, W.T., Beneficial metabolic phenotypes caused by loss-of-function apoc3 mutations. Clin. Genet. 87 (2015), 31–32.
27. [27] Bernelot Moens, S.J., van Capelleveen, J.C., Stroes, E.S., Inhibition of apoC-III: the next pcsk9?. Curr. Opin. Lipidol. 25 (2014), 418–422.
28. [28] Stanhope, K.L., Havel, P.J., Fructose consumption: recent results and their potential implications. Ann. N. Y. Acad. Sci. 1190 (2010), 15–24.
29. [29] Aeberli, I., Zimmermann, M.B., Molinari, L., Lehmann, R., l'Allemand, D., Spinas, G.A., et al. Fructose intake is a predictor of LDL particle size in overweight schoolchildren. Am. J. Clin. Nutr. 86 (2007), 1174–1178.
30. [30] Hobkirk, J.P., King, R.F., Davies, I., Harman, N., Gately, P., Pemberton, P., et al. The metabolic inter-relationships between changes in waist circumference, triglycerides, insulin sensitivity and small, dense low-density lipoprotein particles with acute weight loss in clinically obese children and adolescents. Pediatr. Obes. 9 (2014), 209–217.
31. [31] Caron, S., Verrijken, A., Mertens, I., Samanez, C.H., Mautino, G., Haas, J.T., et al. Transcriptional activation of apolipoprotein C-III expression by glucose may contribute to diabetic dyslipidemia. Arterioscler. Thromb. Vasc. Biol. 31 (2011), 513–519.
32. [32] Sonmez, A., Yilmaz, M.I., Saglam, M., Unal, H.U., Gok, M., Cetinkaya, H., et al. The role of plasma triglyceride/high-density lipoprotein cholesterol ratio to predict cardiovascular outcomes in chronic kidney disease. Lipids Health Dis., 14, 2015, 29.
33. [33] Armato, J., Reaven, G., Ruby, R., Triglyceride/high-density lipoprotein cholesterol concentration ratio identifies accentuated cardio-metabolic risk. Endocr. Pract., 2015, 1–18.
34. [34] Vega, G.L., Barlow, C.E., Grundy, S.M., Leonard, D., DeFina, L.F., Triglyceride-to-high-density-lipoprotein-cholesterol ratio is an index of heart disease mortality and of incidence of type 2 diabetes mellitus in men. J. Investig. Med. 62 (2014), 345–349.
35. [35] Freedman, D.S., Bowman, B.A., Otvos, J.D., Srinivasan, S.R., Berenson, G.S., Levels and correlates of LDL and VLDL particle sizes among children: the Bogalusa heart study. Atherosclerosis 152 (2000), 441–449.
36. [36] Holmes, M.V., Asselbergs, F.W., Palmer, T.M., Drenos, F., Lanktree, M.B., Nelson, C.P., et al. Mendelian randomization of blood lipids for coronary heart disease. Eur. Heart J. 36 (2015), 539–550.
37. [37] Voight, B.F., Peloso, G.M., Orho-Melander, M., Frikke-Schmidt, R., Barbalic, M., Jensen, M.K., et al. Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet 380 (2012), 572–580.
38. [38] Bishop, B.M., Systematic review of cetp inhibitors for increasing high-density lipoprotein cholesterol: where do these agents stand in the approval process?. Am. J. Ther. 22 (2015), 147–158.
39. [39] Miller, N.E., Cetp inhibitors and cardiovascular disease: time to think again. F1000Res., 3, 2014, 124.
40. [40] Gebhard, C., Rhainds, D., Tardif, J.C., HDL and cardiovascular risk: is cholesterol in particle subclasses relevant?. Eur. Heart J. 36 (2015), 10–12.
41. [41] Gugliucci, A., Menini, T., Paraoxonase 1 and HDL maturation. Clin. Chim. Acta 439 (2015), 5–13.
42. [42] Gugliucci, A., Caccavello, R., Nassar, H., Abu Ahmad, W., Sinnreich, R., Kark, J.D., Low protective PON1 lactonase activity in an arab population with high rates of coronary heart disease and diabetes. Clin. Chim. Acta 445 (2015), 41–47.
43. [43] Aviram, M., Vaya, J., Paraoxonase 1 activities, regulation, and interactions with atherosclerotic lesion. Curr. Opin. Lipidol. 24 (2013), 339–344.
44. [44] Kotani, K., Sakane, N., Sano, Y., Tsuzaki, K., Matsuoka, Y., Egawa, K., et al. Changes on the physiological lactonase activity of serum paraoxonase 1 by a diet intervention for weight loss in healthy overweight and obese women. J. Clin. Biochem. Nutr. 45 (2009), 329–334.
45. [45] Yang, Y., Yan, B., Fu, M., Xu, Y., Tian, Y., Relationship between plasma lipid concentrations and HDL subclasses. Clin. Chim. Acta 354 (2005), 49–58.
46. [46] Stanhope, K.L., Bremer, A.A., Medici, V., Nakajima, K., Ito, Y., Nakano, T., et al. Consumption of fructose and high fructose corn syrup increase postprandial triglycerides, LDL-cholesterol, and apolipoprotein-B in young men and women. J. Clin. Endocrinol. Metab. 96 (2011), E1596–E1605.
47. [47] Reinehr, T., Andler, W., Changes in the atherogenic risk factor profile according to degree of weight loss. Arch. Dis. Child. 89 (2004), 419–422.